Karin N Westlund | Chronic Pain Relief | Best Researcher Award

Dr. Karin N Westlund | Chronic Pain Relief | Best Researcher Award

Dr. Karin N. Westlund High is a distinguished neuroscientist and physiologist, currently a Distinguished Professor at UNM School of Medicine and a Research Physiologist at NM VA Health Care. 🇺🇸 She is recognized for her groundbreaking work in pain mechanisms and translational neurobiology. 📚 Her leadership as Vice Chair for Research and longstanding academic contributions span over four decades, advancing the fields of anesthesiology, neuroscience, and chronic pain treatment. 🧠💉

Profile

Education 🎓

Dr. Westlund High earned a B.A. (Zoology) 🎓 from the University of Texas at Austin (1975), followed by an M.A. in Zoology (1976). She received her Ph.D. in Physiology & Biophysics from UTMB Galveston in 1981. 🧪 During her graduate and postdoctoral years, she developed strong expertise in pain pathways and biophysics. 🧬 Her education laid a solid foundation for her influential career in academic medicine and neuroscience research. 📖🧠

Experience 👨‍🏫

From 1982 to the present, Dr. Westlund High has held key roles: tenured professor at UTMB Galveston, University of Kentucky, and UNM. 🏫 She was also Vice Chair for Research at UNM Anesthesiology (2017–2024) and served in VA medical systems in KY & NM. 🏥🧪 She led cell biology graduate programs, taught extensively in medicine and dentistry, and contributed to national research ethics. 🧑‍🏫🧠

Awards & Recognitions 🏅

Dr. Westlund High is the recipient of over 20 prestigious honors, including the Frederick W.L. Kerr Award (2008) 🏆, Innovator of the Year (2023), and multiple NIH awards. 💡 She’s been honored for teaching, research excellence, and innovation, including winning EQUALIZE Pitch Competition and a U.S. patent award (2025). 🇺🇸 She has served on editorial boards and grant panels globally, shaping pain research. 🌍🔬

Research Interests 🔬

Her research centers on pain neurobiology 🔍—investigating trigeminal nerve injury, chronic pain, neuroinflammation, and targeted therapeutic antibodies. 🧠💊 With deep NIH and VA support, she has led studies using translational animal models to discover novel pain relief methods. 🐭⚗️ Her work impacts both clinical and preclinical pain management, with over 40 years of translational insights and innovation. 💥📈

Publications 
  • Role of HDAC5 Epigenetics in Chronic Craniofacial Neuropathic Pain

    International Journal of Molecular Sciences
    2024-06 | Journal article | Author
    CONTRIBUTORS: Sifong Elise Hui; Karin N Westlund
  • Pluripotential GluN1 (NMDA NR1): Functional Significance in Cellular Nuclei in Pain/Nociception

    International Journal of Molecular Sciences
    2023-08 | Journal article | Author
    CONTRIBUTORS: Terry A. McNearney; Karin N Westlund
  • Rapid Generation and Molecular Docking Analysis of Single-Chain Fragment Variable (scFv) Antibody Selected by Ribosome Display Targeting Cholecystokinin B Receptor (CCK-BR) for Reduction of Chronic Neuropathic Pain

    International Journal of Molecular Sciences
    2023-07 | Journal article | Author
    CONTRIBUTORS: Adinarayana Kunamneni; Marena A. Montera; Ravi Durvasula; Dr Sascha Alles; Sachin Goyal; Karin N Westlund

Tran Chau My Thanh | Neuroscience | Young Scientist Award

Dr. Tran Chau My Thanh | Neuroscience | Young Scientist Award

Dr. Tran Chau My Thanh, a dedicated researcher at Duy Tan University, Vietnam 🇻🇳, holds a medical degree and Ph.D. from Hue University of Medicine and Pharmacy 🎓. Her work bridges the gap between clinical medicine and molecular biology 🧬. With a strong passion for translational research, she focuses on using bioinformatics and genomic tools for early diagnosis and targeted therapy development for diseases like cancer, diabetes, and cardiovascular disorders 💉. Through CRISPR/Cas9 and RNA networks, she aims to revolutionize patient-specific treatment pathways 🚀. Her extensive lab experience, scholarly publications, and ongoing innovations make her a promising leader in biomedical science 🏅.

Profile

Education 🎓

Dr. Thanh earned her Medical Degree (M.D.) from Hue University of Medicine and Pharmacy 🏥 and went on to complete her Doctorate (Ph.D.) in the same prestigious institution 🎓. Her education was deeply rooted in both clinical and research training, equipping her with a comprehensive understanding of human health and disease 🧠. Throughout her academic journey, she focused on genomics, molecular medicine, and biotechnology 🔬. The rigorous curriculum and hands-on exposure in advanced labs trained her in modern diagnostic tools and therapeutic innovations ⚙️. She also mastered computational biology and molecular interactions, forming a solid foundation for her groundbreaking work in RNA regulation and gene editing technologies such as CRISPR/Cas9 🧪.

Experience 👨‍🏫

Dr. Thanh brings rich experience as a medical doctor and academic at Duy Tan University 🏫. Her research career spans multiple roles in molecular diagnostics, bioinformatics, and therapeutic innovation 🧬. She has led studies on disease biomarkers, participated in international collaborations 🌐, and worked extensively with cell lines, recombinant DNA, and next-gen sequencing data 🔍. Her proficiency in wet lab and dry lab environments empowers her to integrate experimental biology with computational modeling 🧫💻. Alongside mentoring students and publishing SCI-indexed research, she contributes to translational medicine by connecting bench science to bedside applications, helping advance precision medicine for critical illnesses 💡.

Awards & Recognitions 🏅

Dr. Thanh is a nominee for the Young Scientist Award by the International Cognitive Scientist Awards 🧠🏆. Her impactful work on circular RNAs, miRNAs, and disease biomarker networks has garnered international recognition 🌍. She’s been acknowledged in high-impact journals for discoveries related to coronary heart disease and cancer diagnostics 📖. Her scholarly articles are indexed in SCI and Scopus, and she continues to influence the biomedical community through conference presentations, peer reviews, and academic collaborations 🤝. As a rising figure in molecular biology, her research promises transformative outcomes for early disease detection and targeted therapies 🧬✨.

Research Interests 🔬

Dr. Thanh’s research explores circRNA/miRNA/mRNA interactions, protein-protein networks, and gene function analysis 🧬🧠. She is driven by the quest to discover novel biomarkers for early diagnosis of complex diseases such as cancer, stroke, and diabetes 💊. Her focus includes CRISPR/Cas9 gene editing, molecular docking, and simulations for drug discovery and target validation 💻🧪. She also builds interaction networks to map LncRNA/CircRNA/miRNA/gene/protein-drug relationships, contributing to personalized medicine approaches 🎯. Through bioinformatics, she decodes gene expression dynamics and immune infiltrations to enable efficient diagnostics and therapeutics 💡. Her ultimate goal is to bridge computational biology with translational research for global health improvement 🌐💚.

Publications 

1. Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression
by sponging miRNA-338-3p via regulating the expression of ETS1
2. Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as
potential biomarker for coronary heart disease
3. Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of
bioinformatics data

Marcelo Luis Berthier | Neuroscience| Best Researcher Award

Prof. Marcelo Luis Berthier | Neuroscience| Best Researcher Award

 

Unversidad de Málaga, Spain

Profile

Education

Marcelo Luis Berthier obtained his degree in Medicine (1972-1976) and completed residency training in Neurosurgery (1977-1980), later specializing in Neurology (1980). He served as a staff neurologist at the Institute of Neurological Research, FLENI, Buenos Aires, Argentina (1980-1989), before becoming a research fellow in the Department of Neurology at Clinic Hospital of Barcelona, Spain (1989-1990). From 1991 to 2000, he was a staff neurologist and physician in charge of the Behavioural Neurology Unit at the Clinic University Hospital of Malaga. He earned a PhD in Neuroscience (cum laude) from the University of Malaga and coordinated the Group of Behavioural Neurology and Dementia of the Spanish Neurological Society (2004-2006). In 2004, he founded and directed the Unit of Cognitive Neurology and Aphasia at the Centro de Investigaciones Médico-Sanitarias, University of Malaga, leading it until 2023. Additionally, he served as the director of the Consolidated Research Group on Cognitive Neuroscience: Aphasia and Related Disorders (UNCA, C-12) at the Instituto de Investigación Biomédica de Málaga (IBIMA – Plataforma BIONAND).

Work experience

Dr. Marcelo L. Berthier Torres has led and contributed to several groundbreaking research projects in cognitive neurology and aphasia. As a co-investigator, he participated in the Telerehabilitation in Aphasia project (2021-2023), which evaluated the effectiveness of telerehabilitation compared to face-to-face therapy and identified predictive biomarkers of response, funded by the Junta de Andalucía. He also served as the principal investigator for a study on the efficacy of combined treatment with donepezil, intensive rehabilitation, and transcranial direct current stimulation in chronic post-stroke aphasia (2016-2019), funded by the Instituto de Salud Carlos III. Additionally, he has contributed to the Proyectos de Generación de Conocimiento “Frontera”, an initiative under the FEDER Andalucía 2014-2020 program, which investigates brain biomarkers for individualized treatment approaches in chronic post-stroke aphasia

Areas of Research

Dr. Marcelo L. Berthier Torres has made significant contributions to the treatment of post-stroke aphasia and speech-language disorders. He conducted the first open-label and randomized, placebo-controlled, double-blind trials investigating the use of cognitive-enhancing drugs (donepezil and memantine) alone and in combination with standard aphasia therapy or intensive language-action therapy (ILAT) in chronic post-stroke aphasia. His pioneering studies stimulated international research on aphasia pharmacotherapy, leading to clinical translation. Today, donepezil and memantine, alone or combined with therapy, are widely used off-label for post-stroke aphasia and language disturbances associated with neurodegenerative disorders like Alzheimer’s disease and primary progressive aphasia.

Publication

  • Revisiting the boundaries of different altered accents profiles

    Cortex
    2025-03 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Ignacio Moreno-Torres; Jo Verhoeven; Guadalupe Dávila
  • Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

    CNS Drugs
    2023-07 | Journal article
    CONTRIBUTORS: Guadalupe Dávila; María José Torres-Prioris; Diana López-Barroso; Marcelo L. Berthier
  • Pharmacotherapy for post-stroke aphasia: what are the options?

    Expert Opinion on Pharmacotherapy
    2023-07-24 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Guadalupe Dávila
  • Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia

    Brain Structure and Function
    2023-05-31 | Journal article
    CONTRIBUTORS: Diana López-Barroso; José Paredes-Pacheco; María José Torres-Prioris; Guadalupe Dávila; Marcelo L. Berthier
  • Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia

    Aphasiology
    2022-11-02 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Daniel Santana-Moreno; Álvaro Beltrán-Corbellini; Juan C. Criado-Álamo; Lisa Edelkraut; Diana López-Barroso; Guadalupe Dávila; María José Torres-Prioris